Navigation Links
Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
Date:5/14/2008

civir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: (609) 613-4125

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials (including, without limitation, the two additional cohorts of our ongoing Phase 1 clinical trial of R7128) and/or our development of our product candidates, the risk that R7128 shows no activity in HCV genotype 2 or 3 patients, the risk that we cannot enroll enough patients for the Phase 3 registration clinical trial for clevudine, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2007 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
10. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
11. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... BRIDGEWATER, N.J. , Dec. 15, 2014 ... US (EURONEXT: SAN and NYSE: SNY) are collaborating with ... Cholesterol Counts , an awareness program that will ... and the risks associated with high LDL-C (bad cholesterol). ... .com to take a brief poll and answer ...
(Date:12/15/2014)... Investor-Edge has initiated coverage on the following equities: Zogenix ... (NYSE: LLY ), Nektar Therapeutics (NASDAQ: ... AG (NYSE: NVS ). Free research on these ... On Friday, December 12, 2014, the NASDAQ Composite ended ... 1.79%, to finish the day at 17,280.83, and the S&P ...
(Date:12/15/2014)... , Dec. 15, 2014  Stephen Squires, CEO ... Quantum Materials Corp (OTCQB:QTMM), will be speaking ... Quantum Materials (RCQM) on December 16th, 2014. The RCQM ... exotic nanomaterials in attracting top faculty and students and ... collaborate on research. "We have a ...
Breaking Medicine Technology:Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 2Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 3
... the U.S. Department of Health and Human Services (HHS) ... flexible benefits in the exchanges, the Institute of Medicine ... some powerful special interests that benefit from costly new ... A new survey shows ...
... U.S. Food and Drug Administration and the Centers for ... review" pilot program for concurrent review of medical devices ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) The FDA ... procedures for voluntary participation and guiding principles that the ...
Cached Medicine Technology:PCMA on IOM Essential Health Benefits Report: Employers and Special Interests Will Spar Over Costly Prescription Drug Mandates 2FDA, CMS Launch Pilot Program for Voluntary Parallel Review of Innovative Devices 2
(Date:12/17/2014)... 16, 2014 (HealthDay News) -- Poor students get more fruits ... new study finds. But, the opposite is true for ... fruits and vegetables at school may give a healthy boost ... no matter what the family income level, students all ate ... study found. The study was published recently in the ...
(Date:12/15/2014)... 15, 2014 A recent survey found ... women as impacting skin health and beauty were: “Connections,” ... skin care.” Water and health advocate and radio host ... article describing the survey and the Four C’s.* Kleyne ... every category discussed would benefit from paying attention to ...
(Date:12/15/2014)... December 15, 2014 SIMpalm, a leading ... Connect App” for iPhone for its client, which allows ... is a company, specialized in finding the right wine. ... engine that uses combined sensory, chemistry and wine information. ... a virtual “wine fingerprint.” Those wines that are close ...
(Date:12/15/2014)... 15, 2014 The increase in prevalence of ... the main factors which is contributing to the growth in ... diagnosis and treatment of hearing loss and balance disorders are ... parts - microphone, speaker and amplifier. The global market is ... 6.01% during the period from 2014 to 2019. Some of ...
(Date:12/15/2014)... Bacteroides is becoming the indicator of choice for ... prevalent than coliforms, it cannot reproduce in the presence of ... Key Benefits of the new Bacteroides Sewage Screen:, ... Eliminates false positives from coliforms naturally occurring in the environment ... Maintain the same sampling method with results as quick ...
Breaking Medicine News(10 mins):Health News:Poor Students Eat Healthier Foods at School, Study Finds 2Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 2Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 3Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4
... scientific, technical and medical information products and services, ... Initial Psychotherapy Interview , has received the 2011 ... Society for the Psychological Study of Lesbian, Gay, ... a Gold Medal Life Achievement Award from the ...
... Reporter , WEDNESDAY, Aug. 24 (HealthDay News) -- The percentage ... 14 percent from 22 percent in 2008, a new survey ... the September issue of Obstetrics & Gynecology , don,t ... according to those on both sides of the abortion debate. ...
... Reporter , WEDNESDAY, Aug. 24 (HealthDay News) -- ... may help prevent life-threatening complications of chronic obstructive ... are commonly referred to as acute exacerbations, and ... Although numerous medications are available to help prevent ...
... -- Rheumatoid arthritis patients who believe in their ability ... are more likely to reach those objectives, researchers have ... achieve their physical activity goals have lower levels of ... Researchers in the Netherlands conducted an initial assessment of ...
... patients with rheumatoid arthritis (RA) who have higher levels ... achieve their physical activity goals. According to the study ... a journal of the American College of Rheumatology (ACR), ... self-reported arthritis pain and increased health-related quality of life ...
... Vanderbilt University has been awarded a $4.85 million grant ... to manage the newly established MacArthur Foundation Research Network ... on Law and Neuroscience is examining multiple effects of ... neuroscience accessible and beneficial to America,s courtrooms. The network ...
Cached Medicine News:Health News:Elsevier congratulates Dr. Charles Silverstein upon his receipt of 2 awards 2Health News:Only 1 in 7 Ob/Gyns Now Performs Abortions, Survey Finds 2Health News:Only 1 in 7 Ob/Gyns Now Performs Abortions, Survey Finds 3Health News:Long-Term Antibiotic Use May Lessen COPD Flare-Ups 2Health News:Long-Term Antibiotic Use May Lessen COPD Flare-Ups 3Health News:Achieving realistic physical activity goals benefits RA patients 2Health News:Landmark law and neuroscience network expands at Vanderbilt 2Health News:Landmark law and neuroscience network expands at Vanderbilt 3
This is a single-action instrument that features a spring handle....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The ACMI™ line of laparoscopic hand instruments is designed to provide a wide selection of popular surgical devices to meet procedural needs....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
Medicine Products: